LATE EFFECTS CONSENSUS CONFERENCE

自诞生以来，放射肿瘤学比任何其他癌症都要多 治疗学科，已经考虑了治疗对 正常的组织和器官。急性呼吸道感染的强度之间的差异 和后遗症以及无法预测最终的表现 晚期正常组织损伤的研究使执业的放射肿瘤学家 认识到细心的病人随访的重要性。不仅是早早地 躯体功能和结构的变化发生在实际的 治疗本身，但迟发效应在急性发作后数月至数年内显现 效果会痊愈，而且通常会随着时间的推移而进步。推荐一位 统一制度是建立在共识基础上的理想最终产品 Criteria.‘1985年9月，NCI就毒性问题举行了共识会议 在马里兰州巴尔的摩举行。一个小组委员会，由来自 在这次会议上成立了几个合作小组，目的是 解决标准化毒性影响标准的问题。大部分 这些建议已在《共同毒性》中生效。 NCI于1988年首次发布了标准(CTC)。还有什么要做的 是为亚急性和慢性(晚期)设计CTC的附加物 综合模式治疗策略的毒性，包括 放射治疗。这次后效会议的目的将是 分析当前急性和晚期效应的评分系统，并发展 体现设计简单性并将导致精确度的系统 细节的问题。本会议将特别关注 开发适用于所有站点的评分系统，并建议 验证它们的方法。这可以通过开发 剂量限制正常组织或器官的纵向研究 在合作小组环境中进行。参会人员 将承担提出这些建议的责任，并 方法放到适当的合作小组中，每个方法都可以 从属关系。虽然针对干预措施的研究进展 改善急性和预防后遗症将是我们期望的目标之一 这超出了本会议的范围。

Since its inception, Radiation Oncology, more than any other cancer treatment discipline, has considered the late effects of therapy on normal tissues and organs. The disparity between the intensity of acute and late effects and the inability to predict the eventual manifestations of late normal tissue injury has made practicing radiation oncologists recognize the importance of careful patient follow-up. Not only do early somatic functional and structural alterations occur during the actual treatment itself, but late effects manifest months to years after acute effects heal, and often progress with time. A recommendation of a uniform system is the desired end product based upon 'consensus criteria.' In September 1985, an NCI Consensus Conference on toxicity was held in Baltimore, MD. A subcommittee, comprised of representatives from several cooperative groups was formed at this meeting with the aim of addressing the question of standardized toxic effects criteria. Most of these recommendations were put into effect in the Common Toxicity Criteria (CTC) first distributed by NCI in 1988. What remains to be done is to devise additions to the CTC for subacute and chronic (late) toxicities from combined modality treatment strategies which include radiotherapy. The purpose of this Late Effects Conference will be analyze the current scoring system for acute and late effects and develop a system which embodies simplicity of design and will result in accuracy of detail. The Conference will concern itself specifically with the development of scoring systems to be used in all sites and to recommend methods to validate them. This could be achieved through development of longitudinal studies of the dose-limiting normal tissues or organs to be conducted in cooperative group settings. The conference participants will assume the responsibility of moving these recommendations and methods into the appropriate cooperative group with which each may be affiliated. While the development of studies for interventions to ameliorate acute and prevent late effects will be one of the desired ends this is beyond the scope of this Conference.